RAREのニュース
Ultragenyx to Participate in Gene Therapy Panel at Wedbush PacGrow Healthcare Conference 2021/08/04 12:30:00 Intrado Digital Media
NOVATO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company''s Chief Executive Officer and President will participate in a panel titled Miss Con-GENE-iality - Updates in Gene Tx on Wednesday, August 11, 2021 at the Wedbush PacGrow Healthcare Conference at 12:00 PM ET.
Ultragenyx Pharmaceutical (RARE) Investor Presentation - Slideshow 2021/08/03 14:50:57 Seeking Alpha
Ultragenyx Pharmaceutical Inc.''s (RARE) CEO Emil Kakkis on Q2 2021 Results - Earnings Call Transcript 2021/08/03 04:28:09 Seeking Alpha
Ultragenyx Reports Second Quarter 2021 Financial Results and Corporate Update 2021/08/02 20:05:00 Intrado Digital Media
Second quarter 2021 total revenue of $87.0 million including Crysvita 1 revenue to Ultragenyx of $44.7 million
Ultragenyx''s mRNA encoding enzyme receives FDA Orphan Drug designation 2021/06/24 20:50:16 Seeking Alpha
Ultragenyx Pharmaceutical Inc. (RARE) gains 0.9950% for June 09 - Equities News 2021/06/14 00:30:26 Equities
Ultragenyx Pharmaceutical Inc. (RARE) gains 0.9950% for June 09 Equities.com
Regulatory actions for June 11, 2021 2021/06/11 15:00:00 BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acer, Direct, Genetx, Moderna, Purdue, Soligenix, Ultragenyx.
Ultragenyx to Present at Jefferies Virtual Healthcare Conference 2021/05/26 12:31:00 GlobeNewswire
NOVATO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company''s Chief Executive Officer and President, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 PM ET.
Ultragenyx Pharmaceutical Inc. (RARE) gains 0.9950% for June 09 - Equities News 2021/06/14 00:30:26 Equities
Ultragenyx Pharmaceutical Inc. (RARE) gains 0.9950% for June 09 Equities.com
Regulatory actions for June 11, 2021 2021/06/11 15:00:00 BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acer, Direct, Genetx, Moderna, Purdue, Soligenix, Ultragenyx.
Ultragenyx to Present at Jefferies Virtual Healthcare Conference 2021/05/26 12:31:00 GlobeNewswire
NOVATO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company''s Chief Executive Officer and President, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 PM ET.
Ultragenyx Pharmaceu (RARE) falls 2.52% for May 19 2021/05/19 22:00:21 Equities
Ultragenyx Pharmaceu (NASDAQ: RARE) shares fell -2.52% to end trading Wednesday at $108.62 per share - a net change of $-2.81. Shares traded between $112.78 and $107.71 throughout the day. 232646 shares of Ultragenyx Pharmaceu exchanged hands. Visit Ultragenyx Pharmaceus profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Ultragenyx Pharmaceu and to follow the companys latest updates, you can visit the companys profile page here: Ultragenyx Pharmaceus Profile . For more news on the financial markets be sure to visit Equities News . Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. Sources: Chart is provided by TradingView based on 15-minute-delayed prices.